Results 301 to 310 of about 116,751 (358)

Reducing Emotional Distress with Open-Label Placebos: Assessing the Role of Motor Engagement in Pill Consumption. [PDF]

Behav Sci (Basel)
Schienle A, Kogler W.
europepmc   +1 more source

A Randomized Placebo-Controlled Comparison of Amlodipine and Atenolol in Mild to Moderate Systemic Hypertension

, 1988
William H. Frishman, Richard D. Brobyn, Ronald D. Brown, Brian F. G. Johnson, Robert L. Reeves, Duane G. Wombolt   +5 more
openalex   +1 more source

Transthyretin amyloid cardiomyopathy: Literature review and red‐flag symptom clusters for each cardiology specialty

ESC Heart Failure, Volume 12, Issue 2, Page 955-967, April 2025.
Abstract Wild‐type transthyretin amyloid cardiomyopathy (ATTRwt‐CM) is a progressive and infiltrative cardiac disorder that may cause fatal consequences if left untreated. The estimated survival time from diagnosis is approximately 3–6 years. Because of the non‐specificity of initial symptom manifestation and insufficient awareness among treating ...
Yasuhiro Izumiya, Toru Kubo, Jin Endo, Seiji Takashio, Masatoshi Minamisawa, Jun Hamada, Tomonori Ishii, Hajime Abe, Hiroaki Konishi, Kenichi Tsujita   +9 more
wiley   +1 more source

Efficacy and safety evaluation of Allisartan Isoproxil in patients with hypertension: a meta-analysis. [PDF]

Front Cardiovasc Med
Zhao F, Liu Y, Chen L.
europepmc   +1 more source

Meta‐analysis of sotagliflozin, a dual sodium‐glucose‐cotransporter 1/2 inhibitor, for heart failure in type 2 diabetes

ESC Heart Failure, Volume 12, Issue 2, Page 968-979, April 2025.
Abstract Sodium‐glucose co‐transporters (SGLTs) mediate sodium and glucose transport across cell membranes. SGLT2 inhibitors have a recognized place within heart failure (HF) guidelines. We evaluated the effect of sotagliflozin on HF and cardiovascular outcomes in participants with type 2 diabetes. Scopus, Medline, Embase and Central were searched from
Maria Anna Bantounou, Panagiotis Sardellis, Josip Plascevic, Ribeya Awaes‐Mahmood, Justyna Kaczmarek, Daniel Black Boada, Rosa Thuemmler, Sam Philip   +7 more
wiley   +1 more source

Ultra-overt therapy: a novel medical approach centered on patient consciousness. [PDF]

Front Integr Neurosci
Shirbache K, Liaghat A, Saeifar S, Nezameslami A, Shirbacheh A, Nasri H, Namazi H.   +6 more
europepmc   +1 more source

Cardiac remodelling in the era of the recommended four pillars heart failure medical therapy

ESC Heart Failure, Volume 12, Issue 2, Page 1029-1044, April 2025.
Abstract Cardiac remodelling is a key determinant of worse cardiovascular outcome in patients with heart failure (HF) and reduced ejection fraction (HFrEF). It affects both the left ventricle (LV) structure and function as well as the left atrium (LA) and the right ventricle (RV).
Giada Colombo, Tor Biering‐Sorensen, Joao P. Ferreira, Carlo Mario Lombardi, Andrea Bonelli, Andrea Garascia, Marco Metra, Riccardo M. Inciardi   +7 more
wiley   +1 more source

Caffeine Placebo Effect in Sport and Exercise: A Systematic Review. [PDF]

Nutrients
Vega-Muñoz A, Contreras-Barraza N, Salazar-Sepúlveda G, Lay N, Gil-Marín M, Muñoz-Urtubia N.   +5 more
europepmc   +1 more source

The effects of sodium–glucose cotransporter 2 inhibitors on the ‘forgotten’ right ventricle

ESC Heart Failure, Volume 12, Issue 2, Page 1045-1058, April 2025.
Abstract With the progress in diagnosis, treatment and imaging techniques, there is a growing recognition that impaired right ventricular (RV) function profoundly affects the prognosis of patients with heart failure (HF), irrespective of their left ventricular ejection fraction (LVEF).
Liangzhen Qu, Xueting Duan, Han Chen
wiley   +1 more source

A Systematic Review of Study Design and Placebo Controls in Psychedelic Research. [PDF]

Psychedelic Med (New Rochelle)
Wen A, Singhal N, Jones BDM, Zeifman RJ, Mehta S, Shenasa MA, Blumberger DM, Daskalakis ZJ, Weissman CR.   +8 more
europepmc   +1 more source